Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Perioperative prophylaxis,Treatment of respiratory tract infections,Urinary tract infections (UTIs),Skin and soft tissue infections,Biliary tract infections,Bone and joint infections,Septicemia,Endocarditis
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
1-2 g IV every 8 hours for moderate to severe infections; 2 g IV every 6-8 hours for life-threatening infections.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
1.8 hours (normal renal function); prolonged to 10-12 hours in ESRD; clinical context: dosing interval adjustment required for Cr Cl <55 m L/min
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Cefazolin is not significantly metabolized; it is primarily excreted unchanged in the urine via renal tubular secretion and glomerular filtration.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary (minimal, <1%); fecal (<1%)
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
80-86% bound to albumin
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
0.12-0.14 L/kg; clinical meaning: low Vd indicates limited extravascular distribution, primarily confined to extracellular fluid
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
IM: nearly 100%
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
Cr Cl 30-60 m L/min: 1-2 g every 12 hours; Cr Cl 10-29 m L/min: 1-2 g every 24 hours; Cr Cl <10 m L/min: 1-2 g every 48 hours.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
No dose adjustment required for hepatic impairment; dose based on renal function.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
50-100 mg/kg/day IV divided every 8 hours; for severe infections up to 100 mg/kg/day divided every 6-8 hours; maximum 6 g/day.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Initial dosing based on renal function; monitor Cr Cl and adjust per renal guidelines; age-related decline in renal function necessitates careful dose calculation.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
None.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity reactions including anaphylaxis,Clostridium difficile-associated diarrhea,Renal impairment requiring dose adjustment,Coagulation abnormalities (prolonged prothrombin time),Superinfection with resistant organisms
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
Hypersensitivity to cefazolin or other cephalosporins,Hypersensitivity to penicillins (potential cross-sensitivity)
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
No significant food interactions. No dietary restrictions required. May be administered without regard to meals.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Cefazolin is pregnancy category B. No evidence of teratogenicity in animal studies; however, adequate human studies are lacking. Use in first trimester generally avoided unless clearly needed. No known fetal risks in second and third trimesters.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Cefazolin is excreted into breast milk in low concentrations (M/P ratio ~0.03). Considered compatible with breastfeeding; potential for infant gut flora alteration and diarrhea. Minimal risk to nursing infant.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
Increased renal clearance in pregnancy may require higher doses (e.g., 1-2 g every 6-8 hours) compared to non-pregnant adults. Monitor for therapeutic efficacy.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
First-generation cephalosporin; ensure renal dose adjustment in Cr Cl < 55 m L/min; use for surgical prophylaxis within 60 minutes prior to incision; no cross-allergy absolute with penicillins (approx 5-10% risk); monitor for Clostridioides difficile diarrhea.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
This medication is an antibiotic given intravenously (IV) to treat or prevent bacterial infections.,Inform your healthcare provider if you have any allergies, especially to penicillins or cephalosporins.,Report any signs of allergic reaction: rash, itching, swelling, difficulty breathing.,Take the full course of therapy as prescribed; do not stop early even if you feel better.,Notify your doctor if you develop severe diarrhea, especially if watery or bloody.,This product contains sodium; consult your doctor if you are on a sodium-restricted diet.
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% vs ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER, answered by our medical review team.
AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Cefazolin is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. The standard adult dose of ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: 1-2 g IV every 8 hours for moderate to severe infections; 2 g IV every 6-8 hours for life-threatening infections.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% and ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . ANCEF IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Cefazolin is pregnancy category B. No evidence of teratogenicity in animal studies; however, adequate human studies are lacking. Use in first trimester generally avoided unless cle. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.